Guest guest Posted September 15, 2005 Report Share Posted September 15, 2005 Hi, It turns out that the Sutent drug inhibits c-kit and not bcr-abl. Gleevec inhibits both of them. The Sutent drug helps about 60% of the GIST patients who fail on Gleevec. An excellent site for GIST. Worth joining. http://www.gistsupport.org/ A complete description http://www.gistsupport.org/SU11248.html Sutent (formerly SU-11248, sunitinib malate) Sutent is a tyrosine kinase inhibitor that has anti-cancer and anti-angiogenesis effects. It was previously known as SU-11248, and its chemical name is sunitinib malate. The cellular targets of this drug include FLT3, KIT, PDGRFA, and VEGF-2. It has been tested against gastrointestinal stromal tumor (GIST) and several other types of cancer in clinical trials. On August 10, 2005 Pfizer released the following announcement about submitting Sutent to the FDA for consideration of approval on fast-track status: Pfizer Submits Application for Sutent to FDA NEW YORK, August 10 -- Pfizer Inc said today that it has submitted a New Drug Application for its cancer medicine SU11248 (sunitinib malate), known as Sutent, to the U.S. Food and Drug Administration. Pfizer is seeking FDA approval for Sutent as a treatment for malignant gastrointestinal stromal tumor and metastatic renal cell carcinoma among patients whose tumors do not respond to or do not tolerate standard treatment options. The FDA has granted Sutent fast-track status since Sutent may provide significant benefit over existing therapy for serious or life-threatening illnesses for which no therapy exists. Sutent is an oral, multi-targeted cancer therapy that combines anti-angiogenic and anti-tumor activity to simultaneously stop the blood supply to and directly attack tumor cells. Over 2,000 patients have received Sutent as part of Pfizer's clinical trial program. Developed by Pfizer, Sutent also is being studied alone and in combination with other medicines as a treatment for a number of other solid tumors, including breast, lung, prostate, and colorectal cancers. Sutent is one of the first in a new class of drugs that selectively targets multiple protein receptors, called receptor tyrosine kinases (RTKs). Inhibition of these RTKs is believed to starve tumors of blood and nutrients needed for growth and simultaneously kill the cancer cells that make up tumors. Pfizer is committed to advancing the scientific understanding of cancer and to bringing new medicines that address unmet medical needs to cancer patients. Oncology is a research priority for Pfizer, with a significant portion of the company's research and development investment devoted to discovering and developing innovative therapies for treating breast, colorectal and other cancers. In May 2005 the results of a Phase III trial assessing the efficacy and safety of Sutent against gastrointestinal stromal tumor (GIST) were reported at the ASCO meeting (abstract 4000). SUTENT showed benefit to about 60% of imatinib-resistant patients in the trial. The following link takes you to the abstract of this presentation and allows you to click “audio & slides” to hear the presentation and see the slides shown. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST G. D. Demetri, A. T. van Oosterom, M. Blackstein, C. Garrett, M. Shah, M. Heinrich, G. McArthur, I. Judson, C. M. Baum, P. G. Casali Here are links to other ASCO 2005 presentations about use of Sutent for GIST. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) R. G. Maki, J. A. Fletcher, M. C. Heinrich, J. A. , S. , J. Desai, K. Scheu, C. D. Fletcher, C. Baum, G. D. Demetri Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST) A. van den Abbeele, Y. Melenevsky, D. de Vries, J. Manola, P. Dileo, R. Tetrault, C. Baum, R. Badawi, G. Demetri Availability of Sutent Following the halt of the Phase III trial, manufacturer Pfizer is making Sutent available through some of the former trial locations during the interim period until the FDA reviews its application for approval. You can find out more from Emerging Med. In addition, there are several new trials for GIST with experimental combinations of Sutent together with Gleevec and with other drugs. Please contact Emerging Med for more information at http://www.gistsupport.org/clinical1.html or 866-729-1340. You may also want to check the National Cancer Institute trials section at NIH Clinical Trials.gov Papers About Sutent If you would like to read abstracts of other medical papers concerning Sutent, this link displays PubMed listings for recent papers. [ ] What is sutent? Aug. 10, 2005: Pfizer applies for FDA approval of cancer drug Aug 11, 2005 Pfizer is seeking FDA approval for Sutent to treat a rare stomach cancer called GIST (for gastrointestinal stromal tumors) and metastatic renal cell carcinoma among patients whose tumors do not respond to, or do not tolerate, standard treatment options. In a study with Sutent, the drug proved effective in stanching growth of GIST in 385 patients who had developed resistance to the blockbuster cancer drug Gleevec from Novartis. (Houston Chronicle -- Health) Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 16, 2005 Report Share Posted September 16, 2005 Are you saying that Gleevec caused GIST? Was the study completed w/CML patients in mind or was it a coincidence? kisocean <kisocean@...> wrote:Aug. 10, 2005: Pfizer applies for FDA approval of cancer drug Aug 11, 2005 Pfizer is seeking FDA approval for Sutent to treat a rare stomach cancer called GIST (for gastrointestinal stromal tumors) and metastatic renal cell carcinoma among patients whose tumors do not respond to, or do not tolerate, standard treatment options. In a study with Sutent, the drug proved effective in stanching growth of GIST in 385 patients who had developed resistance to the blockbuster cancer drug Gleevec from Novartis. (Houston Chronicle -- Health) Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 17, 2005 Report Share Posted September 17, 2005 No, this study is not saying that Gleevec caused GIST. GIST patients also take Gleevec to treat their disease (Gleevec inhibits c-kit as well as bcr-abl and GIST patients tumors are fueled by c-kit as ours are fueled by bcr-abl). GIST patients can also become resistant to Gleevec just as CML patients can and Sutent is a drug that can be used by GIST patients who become resistant to Gleevec. Dorothy Yrulooknback wrote: > Are you saying that Gleevec caused GIST? Was the study completed w/CML > patients in mind or was it a coincidence? > > kisocean <kisocean@...> wrote:Aug. 10, 2005: Pfizer applies > for FDA approval of cancer drug Aug 11, > 2005 > Pfizer is seeking FDA approval for Sutent to treat a rare stomach > cancer called GIST (for gastrointestinal stromal tumors) and > metastatic renal cell carcinoma among patients whose tumors do not > respond to, or do not tolerate, standard treatment options. In a study > with Sutent, the drug proved effective in stanching growth of GIST in > 385 patients who had developed resistance to the blockbuster cancer > drug Gleevec from Novartis. (Houston Chronicle -- Health) > > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2005 Report Share Posted September 18, 2005 Wow! I didn't know that about c-kit thanks Dorothy... Dorothy Emery <doemery@...> wrote:No, this study is not saying that Gleevec caused GIST. GIST patients also take Gleevec to treat their disease (Gleevec inhibits c-kit as well as bcr-abl and GIST patients tumors are fueled by c-kit as ours are fueled by bcr-abl). GIST patients can also become resistant to Gleevec just as CML patients can and Sutent is a drug that can be used by GIST patients who become resistant to Gleevec. Dorothy Yrulooknback wrote: > Are you saying that Gleevec caused GIST? Was the study completed w/CML > patients in mind or was it a coincidence? > > kisocean <kisocean@...> wrote:Aug. 10, 2005: Pfizer applies > for FDA approval of cancer drug Aug 11, > 2005 > Pfizer is seeking FDA approval for Sutent to treat a rare stomach > cancer called GIST (for gastrointestinal stromal tumors) and > metastatic renal cell carcinoma among patients whose tumors do not > respond to, or do not tolerate, standard treatment options. In a study > with Sutent, the drug proved effective in stanching growth of GIST in > 385 patients who had developed resistance to the blockbuster cancer > drug Gleevec from Novartis. (Houston Chronicle -- Health) > > > > > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.